LOS ANGELES–(BUSINESS WIRE)–Caldera Medical, a leader in women’s health solutions, is proud to announce the appointment of John Pitstick as its new Chief Financial Officer & EVP Corporate Development. With a strategic focus on advancing Caldera Medical’s position in the women’s health sector, Caldera Medical completed its acquisition of Atlantic Therapeutics based in Galway Ireland on September 1st of this year and maintains an innovation and operations team in Ireland as its European headquarters. John’s appointment aligns with the company’s accelerated growth and ambitious plans for future acquisitions.
John Pitstick – A Synthesis of Expertise and Vision
John Pitstick began his career with Ernst & Young managing a global client base and contributing to several IPOs. His distinguished career as a CFO is marked by significant achievements in growing both private and publicly traded technology and healthcare companies. John’s financial acumen and strategic insight is underscored by his role as a member of the board of directors of a publicly traded financial services company, where he also serves as chairman of the audit committee.
Driving Growth through Strategic Acquisitions
As CFO, John’s expertise in leading Mergers and Acquisitions (M&A) will be pivotal. His experience in overseeing transactions exceeding $3 billion, coupled with his success in raising over $1 billion in financing, equips him to guide Caldera Medical through its ambitious expansion plans, including strategic acquisitions that will enhance the company’s portfolio and market presence.
About Caldera Medical
Caldera Medical is a medical device company solely focused on women’s health, committed to improving the quality of life for women. Caldera Medical develops, manufactures, and markets surgical products for treating Stress Urinary Incontinence, Pelvic Organ Prolapse, Polyps, and Fibroids. Known for its customer intimacy principle and significant humanitarian program, Caldera Medical is dedicated to treating one million women in underserved populations globally by 2025.